Skip to main content
SpringerLink
Log in

Is the fatigue an adverse event of the second generation of hormonal therapy? Data from a literature-based meta-analysis

  • Short Communication
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

New hormonal therapies have enriched the therapeutic armamentarium for patients with castration-resistant prostate cancer (CRPC). Fatigue is one of the most common adverse events registered in phase III trials of these new drugs. The aim of this article is to perform a meta-analysis based on all available literature data focused on the risk rate (RR) of fatigue from new hormonal agent-based therapy in patients with CRPC. A total of 11,751 cases were included from 11 randomized trials. The analysis revealed that the second generation of hormonal therapies increased the RR of any-grade fatigue (RR = 1.27) and grade 3–4 fatigue (RR = 1.25). This last adverse event was always higher in a pre-chemotherapy setting. In conclusion, given the limitations of a literature-based study, rather than a meta-analysis based on individual patients’ data, our study confirmed the increase in the RR for any-grade and grade 3–4 fatigue during the second generation of hormonal therapies, with particular attention being paid to grade 3–4 in the pre-chemotherapy setting of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Roviello G, Sigala S, Sandhu S, et al. Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: a literature based meta-analysis of randomized trials. Eur J Cancer. 2016;61:111–21.

    Article  CAS  PubMed  Google Scholar 

  2. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48.

    Article  CAS  PubMed  Google Scholar 

  4. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.

    Article  CAS  PubMed  Google Scholar 

  5. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Fizazi K, Jones R, Oudard S, et al. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol. 2015;33(7):723–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Saad F, Fizazi K, Jinga V, et al. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol. 2015;16(3):338–48.

    Article  CAS  PubMed  Google Scholar 

  8. Forlenza MJ, Hall P, Lichtenstein P, et al. Epidemiology of cancer-related fatigue in the Swedish twin registry. Cancer. 2005;104(9):2022–31.

    Article  PubMed  Google Scholar 

  9. Lindqvist O, Rasmussen BH, Widmark A. Experiences of symptoms in men with hormone refractory prostate cancer and skeletal metastases. Eur J Oncol Nurs. 2008;12(4):283–90.

    Article  PubMed  Google Scholar 

  10. Chen AC, Petrylak DP. Complications of androgen deprivation therapy in men with prostate cancer. Curr Oncol Rep. 2004;6(3):209–15.

    Article  PubMed  Google Scholar 

  11. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.

    CAS  PubMed  Google Scholar 

  12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.

    Article  CAS  PubMed  Google Scholar 

  13. Shore ND, Chowdhury S, Villers A, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol. 2016;17:153–63.

    Article  CAS  PubMed  Google Scholar 

  14. Penson DF, Armstrong AJ, Concepcion R, et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial. J Clin Oncol. 2016;34:2098–106.

    Article  CAS  PubMed  Google Scholar 

  15. Cathomas R, Crabb SJ, Mark M, et al. Orteronel switch maintenance therapy in metastatic castration resistant prostate cancer after first-line docetaxel: a multicenter, randomized, double-blind, placebo-controlled trial (SAKK 08/11). Prostate. 2016;76:1519–27.

    Article  CAS  PubMed  Google Scholar 

  16. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352–60.

    Article  CAS  PubMed  Google Scholar 

  18. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–92. Erratum in: Lancet Oncol. 2012;13(11):e464, Lancet Oncol. 2014;15(9):e365.

  19. Rathkopf DE, Smith MR, de Bono JS, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014;66(5):815–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Beer TM, Armstrong AJ, Rathkopf D, et al. Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol. 2017;71(2):151–4.

    Article  CAS  PubMed  Google Scholar 

  21. Sternberg CN, Molina A, North S, Mainwaring P, Fizazi K, Hao Y, Rothman M, et al. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Ann Oncol. 2013;24(4):1017–25.

    Article  CAS  PubMed  Google Scholar 

  22. Ryan JL, Carroll JK, Ryan EP, et al. Mechanisms of cancer-related fatigue. Oncologist. 2007;12(Suppl 1):22–34.

    Article  CAS  PubMed  Google Scholar 

  23. Mitchell SA, Beck SL, Hood LE, et al. Putting evidence into practice: evidence based interventions for fatigue during and following cancer and its treatment. Clin J Oncol Nurs. 2007;11(1):99–113.

    Article  PubMed  Google Scholar 

  24. Roviello G, Petrioli R, Laera L, Francini E. The third line of treatment for metastatic prostate cancer patients: option or strategy? Crit Rev Oncol Hematol. 2015;95:265–71.

    Article  PubMed  Google Scholar 

  25. Francini E, Petrioli R, Roviello G. No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide. Expert Rev Anticancer Ther. 2014;19:1–6.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Department of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, Via Padre Pio 1, 85028, Rionero in Vulture, PZ, Italy

    Giandomenico Roviello

  2. Department of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129, Trieste, Italy

    Giandomenico Roviello & Daniele Generali

  3. Breast Cancer Unit and Translational Research Unit, ASST Cremona, Viale Concordia 1, 26100, Cremona, Italy

    Daniele Generali

Authors
  1. Giandomenico Roviello
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniele Generali
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giandomenico Roviello.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 175 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Roviello, G., Generali, D. Is the fatigue an adverse event of the second generation of hormonal therapy? Data from a literature-based meta-analysis. Med Oncol 35, 29 (2018). https://doi.org/10.1007/s12032-018-1081-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-018-1081-z

Keywords

Search

Navigation